The clinical relevance of the research described in this paper is manyfold. First, due to the extent of our series, which includes by far the largest series of IBC samples ever reported, we were able to delineate the molecular profile of IBC with enhanced accuracy, taking into account various points of criticism raised with respect to earlier studies. Our report is the first to analyze the expression profiles of IBC samples in light of a uniform case definition for IBC put forward by an international expert panel.
Statement of Translational Relevance
The clinical relevance of the research described in this paper is manyfold. First, due to the extent of our series, which includes by far the largest series of IBC samples ever reported, we were able to delineate the molecular profile of IBC with enhanced accuracy, taking into account various points of criticism raised with respect to earlier studies. Our report is the first to analyze the expression profiles of IBC samples in light of a uniform case definition for IBC put forward by an international expert panel.
Also, the present study is the first to deal with the fact that the differential distribution pattern of the molecular subtypes between IBC and nIBC affects its outcome.
Further, our data suggest that differentially expressed genes between IBC and nIBC in a molecular subtype independent manner hold the fingerprints of aggressive breast tumor behavior. Therefore, our expression series not only suits IBC research, but might also be instrumental for scientists focused on breast cancer invasion and metastasis in general. Finally, this study gives voice to the World IBC Consortium, which is founded to foster collaborations between researchers active within the IBCcommunity. We believe that our effort is an example of how collaborations with a strong international backbone can prosper research well into the 21th century.
Introduction
Inflammatory breast cancer (IBC) is an aggressive form of locally advanced breast cancer. At the time of diagnosis, virtually all patients have lymph node metastases, and one third of the patients have metastases in distant organs.
Consequently, patient prognosis is poor (1) . The rate of pathological complete response (pCR) after primary anthracycline-based chemotherapy (CT) ranges from 15 to 30%, and the 5-year survival remains around 40%. Currently, IBC remains a poorly characterized disease lacking specific molecular targets for therapy, although ErbB2 is often amplified.
The low frequency of occurrence (approximately 5% of all breast tumors) combined with the small size of diagnostic samples, in addition to the fact that patients with IBC are treated with neo-adjuvant chemotherapy, are the factors that have hampered past molecular studies, specifically those that were directed at deciphering the molecular biology of this disease by genome-wide approaches (2) .
The major stumbling block has been the poor statistical power when multiple genes (typically a multitude of 10.000) are tested on a small number of samples. High genes/samples ratios, even after removing noisy and non-informative data, result in dramatic downscaling of the significance level (i.e. multiple testing correction) leading to loss of statistical power (3) . gene lists into biological processes or signal transduction pathways, there was significant ambiguity. Potential reasons for this observation have been discussed previously and include: A. distinct case definitions of IBC used across different studies, B. variability of the nIBC control group, C. differences in the characteristics of the IBC and nIBC groups between different studies, notably with respect to the hormone receptor status, and D. inter-study technological differences, i.e. use of different platforms and subsequently different input gene lists (2) .
In 2008, the World IBC Consortium (www.ibcconsortium.org) was founded with the goal of fostering collaborations between international research groups who focus on this rare but aggressive form of breast cancer. The research described in the current paper is the first project spearheaded by the World IBC Consortium and aims at redefining the molecular profile of IBC by taking into account the points of criticism raised with respect to the earlier studies described above. Here, we used a uniform case definition of IBC that has been put forward by an international expert panel (11) .
Using gene expression profiles from Affymetrix (HGU133-series) derived from 3 different sites involved in IBC research, we were able to obtain an unprecedented number of IBC samples (N=137), which allows us to resolve both the sample sizerelated and the platform-related issues identified in the previous studies.
Research. ER and ErbB2 expression were defined using probe sets 205225_at (ESR1) and 216836_s_at (ERBB2) as described previously (12) . As a control, we verified the correlation between mRNA status and immunohistochemistry (IHC)-based protein status as discrete variables. The positive or negative mRNA status was defined using a 2-component Gaussian mixture distribution model as described previously (13) . Table 1) . Tumor grade was determined using the genomic grade index (GGI) (14) . All patients were treated using a multidisciplinary approach according to standard guidelines. Clinicopathological data of our series are shown in 
Materials and Methods

Patients and samples
Data processing and normalization
RNA extraction from the 389 samples and hybridization onto Affymetrix GeneChips (HGU133-series) was performed as described before (6, 8, 9, 15) . Expression data were normalized by GCRMA (16) . For each of the 3 data sets separately, probe sets with expression values above log 2 (100) in at least 1% of the arrays were filtered in. Next, the list of common informative probe sets (N=9.926) was identified. This list was used to merge the distinct data sets. Therefore, we performed regression normalization, using the Limma-package in BioConductor, to remove technical, lab-specific, variation in gene expression between the distinct data sets. A principal component analysis (PCA) was done on the merged data set prior and after the regression normalization to verify the accuracy of the regression normalization in removing the lab-specific variation in gene expression.
Molecular subtypes
We classified each sample in the merged data set according to the molecular subtypes (Luminal A, Luminal B, Basal-like, HER2-enriched and Normal-like) using the PAM50-methodology described by Parker and colleagues (17) . In addition, samples predicted to belong to the Claudin-low subtype by the nine-cell line Claudinlow predictor (18) were considered Claudin-low. To further investigate the effect of the regression normalization on the biological variation in gene expression, the molecular subtype classification was compared with the expression of an ER activation signature (19).
Research. 
Unsupervised analysis
To investigate common themes in gene expression within each tumor phenotype (IBC or nIBC) separately as well as for both tumor phenotypes combined, we adopted the following strategy. We randomly selected 100 samples from the 3 groups of interest (Group 1: IBC, Group 2: nIBC, and Group 3: combined IBC/nIBC).
On this selection, unsupervised hierarchical cluster analysis (UHCA) using Manhattan distance as distance measure and Ward linkage as the dendrogram drawing method was performed only for those genes having a standard deviation greater than 2. UHCA was followed by a cluster robustness analysis using the 
Supervised analyses
Supervised analysis, identifying differentially expressed genes between IBC and nIBC, was performed to evaluate the influence of alternative stage-matching approaches on the identifiable biological differences between IBC and nIBC.
Research. Therefore, global differences in gene expression between IBC and 3 alternatively composed nIBC control groups (Stage I-IV, Stage I-II and Stage III-IV) were investigated using the global test (20) . In addition, for each comparison, we sought to identify lists of differentially expressed genes using Significance Analysis of Microarrays (SAM) (21) . The resulting gene lists were compared.
To further explore functional differences between IBC and nIBC, we repeated supervised analyses at the pathway level. We applied 18 pathway GES originally described by Gatza and colleagues using the procedures outlined in the original publication (19) and one additional GES for VEGF-activation (22) . In addition, for each of the previously defined comparisons, we explored differences in patterns of transcription factor activation. For that purpose, we designed an algorithm to quantify the extent of transcription factor activation in samples based on the gene expression data. Details are provided in the supplementary data file and Supplementary Table 2.
Molecular subtype-independent supervised analysis
Due to the association of the tumor phenotype (IBC/nIBC) with the molecular subtypes, the list of probe sets resulting from the IBC/nIBC comparison probably contains many genes related to molecular subtype, and therefore we hypothesize that this gene list is not IBC-specific. In order to dissect IBC-specific variations in gene expression from molecular subtype-specific variations in gene expression, supervised analysis (IBC vs. nIBC) was repeated by applying linear regression modeling (Limma-package). Prior to analysis, we divided the data set into a training the samples were derived (IPC, MDA, TCRU) were compared between both data sets. The training data set was analyzed using linear regression models incorporating the molecular subtype classification and the IBC/nIBC classification to identify probe sets with IBC-specific expression components. Using the global test (20) , lists of probe sets were analyzed for global expression differences between IBC and nIBC in the validation set. Classifier models based on the identified lists of probe sets with an IBC-specific expression component were constructed using the nearest shrunken centroid algorithm implemented in the PAMR-package. For this purpose, 10-fold cross-validation on the training set was performed to select an appropriate δ-value minimizing the cross-validated training error rate. The resulting models were applied on the validation set to estimate accuracy, sensitivity and specificity. In addition, we tested the performance of the classifier models to discriminate between samples from patients with and without IBC in more homogenous subgroups. For sake of statistical power we combined Luminal A and Luminal B samples into a luminal group and Basal-like and Claudin-low samples into a triple negative breast cancer (TNBC) group. Finally, the strategy of dissecting IBC-specific effects from molecular subtypespecific effects using linear regression models was repeated on the entire data set for the pathway and transcription factor activation data.
Analysis of publicly available nIBC data
Given the higher metastatic risk of IBC compared to nIBC, we tested the hypothesis that our 79-gene IBC/nIBC signature, if biologically relevant, is associated with metastatic relapse in nIBC. Therefore, we collected expression data from 6 publicly available series of adjuvant chemotherapy-and hormone therapy-naive lymph node-negative early breast cancer patients. These series have been used for Table   3 . Redundancy related to patient samples included in multiple data sets was eliminated, yielding 871 samples available for analysis. Before analysis, we mapped hybridization probes for the differentially expressed genes across the two oligonucleotide-based platforms used across the series. When multiple probes were mapped to the same GeneID (EntrezGene identification number), the one with the highest variance in a particular dataset was selected to represent the GeneID.
Analysis of each data set was done separately to guarantee a larger number of genes common with our gene list. After having identified the common genes, we 
Statistical analyses
In the results section, only nominal P-values are reported; however in case of multiple comparisons, P-values were corrected and were considered significant only if the false discovery rate (FDR) was smaller than 0.05 (9). To compare the distribution according to categorical variables, Chi-square testing or the Fisher Exact test were used when appropriate. To compare continuous data between two or more groups, respectively the Mann-Whitney U-test and the Kruskal-Wallis test were used. was used. To compare distributions of continuous variables, Spearman correlation analysis was performed. The distant metastasis-free survival (DMFS) for nIBC patients included in the public data set was calculated from the date of diagnosis until the date of first metastatic relapse. The follow-up was calculated from the date of diagnosis to the date of last news for event-free patients. Survival was calculated using the Kaplan-Meier method and compared between groups with the log-rank test.
Univariate and multivariate analyses were done using generalized linear models or 
IBC/nIBC molecular comparison and influence of the molecular subtypes
We sought to determine differences in gene expression between IBC and nIBC in a gene-by-gene supervised manner. Table 2 provides an overview of the results of this comparison. When comparing IBC to nIBC, we observed significant differences in gene expression, regardless of the type of stage-matching performed for the nIBC control group. On initial review, differences between IBC and advanced stage (III-IV) nIBC seemed smaller than between IBC and all nIBC samples, as suggested by the lower Q-value. However, when differences between IBC samples and non-stage-matched nIBC samples were analyzed in ten equally large series or randomly selected samples, no significant differences for Q-values were recorded (P=0.345), suggesting that the determinant responsible for this difference is sample size and is not due to the type of stage-matching (Table 2 and Figure 2A) 
analyses were performed for the numbers of differentially expressed genes at FDR<0.050 and FDR<0.100 (Table 2 and 
were more activated in nIBC. Among the transcription factors hyperactivated in IBC we identified RELA, corroborating the results from previous studies (24, 25) .
Molecular subtype-independent comparison of IBC and nIBC
Because of the strong correlation between the IBC/nIBC phenotype and the molecular subtypes, we hypothesized that the results presented above could be related to the molecular subtypes, and hence were not actually IBC-specific. Thus, we reiterated the IBC/nIBC comparative analysis (gene expression, pathway activation, and transcription factor activation) using linear regression models to identify probe sets that are differentially expressed between IBC and nIBC in molecular subtype independent manner. In order to be able to evaluate the extent by which the identified probe sets truly reflect IBC biology, we divided our series into a training and validation set. No differences between both sets were observed with respect to the distribution of the molecular subtypes (P=0.955), the tumor stage (P=0.954) and the institution from which the samples were derived (P=0.761).
In the training set, we identified 491 probe sets, representing 443 unique and IBC-specific genes, of which 231 (47%) and 260 (53%) were respectively up-or downregulated in IBC (Supplementary Table 5 ). For comparison, 2743 genes were differentially expressed (FDR<0.050) between IBC and nIBC in the training set when molecular subtype-dependent gene expression differences were not considered.
Within the list of 491 probe sets, 79 probe sets (16%) were uniquely IBC-specific, whereas the remaining probe sets (N=412) showed additional molecular subtype- 
Prognostic value of the IBC/nIBC signature in nIBC
Given the poor prognosis of IBC, we hypothesized that our 79-gene list, if biologically relevant with respect to the IBC/nIBC distinction, might be associated with 
One of the aims of this study was to redefine the molecular profile of IBC, taking into account the points of criticism raised in earlier studies. The issues related to sample size, the definition of IBC cases and the inter-study differences in technical platform are, to the best of our efforts, resolved by the study design but the objections with respect to the composition of the control group remain. Our results clearly demonstrate that the differential distribution of the molecular subtypes between both tumor groups needs to be considered. As shown by unsupervised hierarchical clustering, IBC and nIBC are significantly segregated downstream of the first bifurcation, suggesting that there are major differences in gene expression between the IBC and nIBC tumor phenotypes. However, multivariate regression analysis revealed that the presence of the different molecular subtypes is the main driver of the clustering pattern. Therefore, differences in gene expression between IBC and nIBC are dominated by the differential distribution pattern of the molecular subtypes, which is corroborated by the fact that only 18% of the genes initially reported to be differentially expressed between IBC and nIBC remain differentially expressed after performing the linear regression analysis to account for the influence of the molecular subtypes. Of note, the number of genes with a uniquely IBC-specific gene expression profile is even smaller and represents only 3% of the global expression differences.
The differential pattern of the molecular subtypes, at least in part, explains the higher proportion of samples with a molecular "poor-prognosis" profile in IBC than in nIBC when classified according to previously published prognostic gene signatures, as well as the differential activation of biological pathways (data not shown). On the other hand, the influence of the composition of the control group according to tumor stage appears to be limited. 
We thus decided to compare IBC with nIBC, incorporating all stages (Stage I-IV) of breast cancer and to use regression modeling to discriminate between molecular subtype-specific effects and tumor phenotype-specific effects.
Alternatively, we could have compared IBC to a non-stage-matched but molecular subtype-matched nIBC control group. However, this would lead to smaller sample sizes and, hence, considerable loss of statistical power, a disadvantage not encountered when using the regression models on the entire data set.
The identified IBC-specific molecular changes both confirm results obtained in previous studies and reveal novel findings. MARCKS, a gene that ranked amongst the top 10 differentially expressed genes between IBC and nIBC, is involved in regulating cell motility via its function as a regulator of the actin cytoskeleton (28) . Tables   Table 1: Histo-clinical data of IBC and nIBC samples observe that the majority of the IBC and nIBC samples are correctly classified using both models, when using a cross-validated probability of 0.500 as threshold for classification. Both models were subsequently evaluated in an independent test set. D   25  30  35  40  45  0  500  1000  1500  2000  2500  3000  3500  1000  2000  3000  4000 Research. 
